Chimerix (CMRX) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $10.00 price objective on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Chimerix from a hold rating to a buy rating and set a $5.25 target price for the company in a report on Friday, November 10th. ValuEngine upgraded shares of Chimerix from a strong sell rating to a sell rating in a report on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. Chimerix currently has an average rating of Hold and a consensus price target of $7.06.

Chimerix (NASDAQ:CMRX) opened at $4.65 on Friday. Chimerix has a twelve month low of $4.17 and a twelve month high of $6.64. The stock has a market cap of $219.14, a price-to-earnings ratio of -3.25 and a beta of 1.42.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.81 million. research analysts forecast that Chimerix will post -1.6 earnings per share for the current year.

In related news, insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Chimerix by 19.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,728,095 shares of the biopharmaceutical company’s stock valued at $9,072,000 after purchasing an additional 279,845 shares during the last quarter. State Street Corp raised its position in Chimerix by 7.3% in the 2nd quarter. State Street Corp now owns 828,936 shares of the biopharmaceutical company’s stock valued at $4,515,000 after purchasing an additional 56,600 shares during the last quarter. Northern Trust Corp raised its position in Chimerix by 10.4% in the 2nd quarter. Northern Trust Corp now owns 696,440 shares of the biopharmaceutical company’s stock valued at $3,795,000 after purchasing an additional 65,335 shares during the last quarter. Victory Capital Management Inc. raised its position in Chimerix by 13.9% in the 4th quarter. Victory Capital Management Inc. now owns 256,424 shares of the biopharmaceutical company’s stock valued at $1,187,000 after purchasing an additional 31,340 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Chimerix by 3.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 253,367 shares of the biopharmaceutical company’s stock valued at $1,381,000 after purchasing an additional 8,287 shares during the last quarter. Hedge funds and other institutional investors own 70.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Stock Observer and is the property of of Stock Observer. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thestockobserver.com/2018/02/06/chimerix-cmrx-receives-new-coverage-from-analysts-at-hc-wainwright.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply